This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heartfailure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Heartfailure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. Common predictors include older age, prior hypertension, diabetes and atrial fibrillation. HFrEF is more commonly.
Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heartfailure (HF) with a left ventricular ejectionfraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Heartfailure with preservedejectionfraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: HeartFailure Reveals that Despite Significant Efforts to Improve Acute HeartFailure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Heartfailure with preservedejectionfraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heartfailure with mildly reduced or preservedejectionfraction. Nonresistant hypertension was defined as BP above threshold but not meeting aTRH criteria. per 100 patient-years).
Circulation: HeartFailure, Ahead of Print. BACKGROUND:The therapeutic armamentarium for heartfailure with preservedejectionfraction (HFpEF) remains notably constrained. compared with single condition exposure 5.21.3% (obesity), 6.73.5% (hypertension), and 9.01.1% (diabetes;P<0.001).
Beta-blockers are commonly used in patients with heartfailure and mildly reduced or preservedejectionfraction (HFmrEF/HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER).
Journal of the American Heart Association, Ahead of Print. BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heartfailure with preservedejectionfraction (HFpEF), and it is a strong predictor of adverse outcomes.
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heartfailure (HF) with preservedejectionfraction (HFpEF). Obesity was associated with more first and recurrent heartfailure events.
Objective The heterogeneous pathophysiology of the diverse heartfailure with preservedejectionfraction (HFpEF) phenotypes needs to be examined. We aim to assess differences in the biomarkers among the phenotypes of HFpEF and investigate its multifactorial pathophysiology.
Hypertension, Ahead of Print. Background:We tested the hypothesis that patients with heartfailure with preservedejectionfraction (HFpEF) would have greater muscle sympathetic nerve activity (MSNA) at rest and sympathetic reactivity during a cold pressor test compared with non–heartfailure controls.
What is the safety and efficacy of tadalafil in patients with heartfailure with preservedejectionfraction (HFpEF) and combined postcapillary and precapillary pulmonary hypertension (CpcPH)?
Hypertensive disorders of pregnancy as a risk factor for heartfailure. Hypertensive disorders of pregnancy (HDP) occur in almost 10% of gestations and preeclampsia, a more severe form, in 34%.
Hypertension during pregnancy affects up to 10% of pregnancies and is associated with significant cardiovascular morbidity and mortality. Finally, we explore how future cardiovascular risk may be predicted based on cardiac remodelling during or after pregnancy and suggest potential areas of further research in the field.
About HeartFailureHeartfailure (HF) is a chronic, progressive disease in which the heart cannot pump enough blood to meet the body's needs. HFpEF is HF with preservedejectionfraction in which pressure builds up in the heart and lungs due to a stiffened left ventricle.
Getty Images milla1cf Tue, 01/23/2024 - 13:38 January 23, 2024 — Sequana Medical NV , a pioneer in the treatment of fluid overload in liver disease, heartfailure and cancer, announced that an independent Data and Safety Monitoring Board (DSMB) approved the start of the randomized cohort in MOJAVE , the US Phase 1/2a study of DSR 2.0
Introduction: Patients with ‘heartfailure with preservedejectionfraction’ (HFpEF) frequently manifest chronotropic incompetence as well as hypertension (HTN). Cardiac pacing may improve clinical outcomes in these patients. To date, pacing has not been regulated by an external hemodynamic input.
Introduction:The demographics of patients with pulmonary arterial hypertension (PAH) is shifting towards older age, increased comorbidity burden, and an increase in the risk of left ventricular (LV) diastolic dysfunction. 2022 were included. 2022 were included.
However, It is surprising even in chronic pulmonary hypertension , the degree of RVH is not constant and homogenous.This is because , different parts of RV chamber has different wall thickness.Further, the pressure distribution from PA to RV is uneven. Eur J Heart Fail. Eur J Heart Fail 2016; 18: 226 2018 Jan;20(1):16-37.
Intro:Drug Development for Heartfailure with PreservedEjectionFraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. l) for 8 weeks.
BACKGROUND:Heart failure with preservedejectionfraction (HFpEF) has become the most prevalent type of heartfailure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells. Circulation, Ahead of Print.
The CardioMEMS PA (pulmonary artery) sensor allows remote pulmonary artery diastolic (PAD) pressure monitoring to adjust diuresis in heartfailure with preservedejectionfraction (HFpEF).
Shah, author of Atrial Shunt Device Effects on Cardiac Structure and Function in HeartFailure With PreservedEjectionFraction: The REDUCE LAP-HF II Randomized Clinical Trial. Here is an audio podcast from the primary author published in JAMA network. Interview with Sanjiv J. Hosted by James E.
ET Main Tent (Hall B1) Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients with Elevated Risk For Major Adverse Cardiovascular Events.
Introduction:Heart failure with preservedejectionfraction (HFpEF) is a form of heartfailure which is rapidly rising in incidence in the US today. g/L of an iNOS inhibitor (N-Nitro-L-arginine methylester) to induce hypertension.
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heartfailure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?
Journal of the American Heart Association, Ahead of Print. BackgroundSparce data suggest higher mortality in heartfailure (HF) with left ventricular ejectionfraction (EF) >65% to 70%. We characterized EF distribution, characteristics, and outcomes in patients with HF and EF 50%.Methods
Abstract Aim Pathophysiological differences between patients with heartfailure with preserved (HFpEF) and reduced (HFrEF) ejectionfraction (EF) remain unclear. Study design and main study results. In HFrEF, interleukin (IL)-8 and IL-6 were possible targets related to lower EF and worsening renal function.
Journal of the American Heart Association, Ahead of Print. BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heartfailure (HF). Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2.
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heartfailure that has had few therapeutic options.
AFMR is likely to become more common with population ageing, alongside increases in atrial fibrillation and heartfailure with preservedejectionfraction; conditions causing atrial dilatation. Advancing age and pulmonary hypertension independently associated with survival in FMR.
ObjectiveThe left atrial stiffness index (LASI) holds significance in the atrioventricular coupling function and heartfailure progression. To assess left atrial function and evaluate the relationship between LASI and exercise capacity in hypertension-related heartfailure with preservedejectionfraction (HT-HFpEF).MethodsThe
42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. In the U.S.,
Aims Pulmonary hypertension (PHT) appears to be very common in heartfailure with preservedejectionfraction but details on its prevalence, severity and prognostic implications have not been well defined.
HeartFailure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heartfailure hospitalizations and cardiovascular mortality among patients with preservedejectionfraction (HFpEF).
We report from the 19 th Annual Scientific Meeting of the Cardiorenal Forum held in London on 4 th October 2024, which served as a dynamic platform for experts in cardiology, diabetes, and renal medicine to converge and exchange the latest insights on managing heart and kidney failure.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content